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Aim To estimate the incidence and mortality trends of gas-
tric and colorectal cancers in Croatia between 1988 and 
2008.
Methods Incidence data for the period 1988-2008 were 
obtained from the Croatian National Cancer Registry. The 
number of deaths from gastric and colorectal cancers were 
obtained from the World Health Organization mortality da-
tabase. Joinpoint regression analysis was used to describe 
changes in trends by sex.
Results Gastric cancer incidence rates declined steadily 
during the study period, with estimated annual percent 
change (EAPC) of -3.2% for men and -2.8% for women. 
Mortality rates in men decreased, with EAPC of -5.0% from 
1988-1995 and -2.5% from 1995-2008. Mortality rates in 
women  decreased,  with  EAPC  of  -3.2%  throughout  the 
study period. For colorectal cancer in men, joinpoint anal-
ysis revealed increasing trends of both incidence (EAPC 
2.9%) and mortality (EAPC 2.1%). In women, the increase in 
incidence was not significant, but mortality rates in the last 
15 years showed a significant increase (EAPC 1.1%).
Conclusion The incidence and mortality trends of gastric 
cancer in Croatia are similar to other European countries, 
while the still increasing colorectal cancer mortality calls 
for more efficient prevention and treatment.
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The two most important gastrointestinal cancers in Croa-
tia are gastric and colorectal cancer, which together con-
tribute to about one fifth of Croatian cancer incidence and 
mortality (1).
Gastric cancer
Gastric cancer is the fourth most common cancer and the 
second  leading  cause  of  cancer  death  worldwide  (1,2), 
with high case fatality rate and five-year survival of less 
than 20% (3). It displays a substantial geographic variability 
across the continents, with rates in Asia, some parts of East-
ern Europe, and Latin America being several times higher 
than those in western countries (2).
The etiology of gastric cancer has not been entirely eluci-
dated. The most common risk factors reported in the litera-
ture are chronic mucosal infection with Helicobacter pylori 
(4), consumption of salt and salt-preserved foods (5), low 
socio-economic status (6), presence of contaminants in 
drinking water (7,8), smoking (9), and certain occupational 
exposures (10,11).
During the second half of the 20th century, incidence and 
mortality  rates  of  gastric  cancer  have  declined  steeply 
throughout Europe (12,13) and around the world (14), mainly 
as a result of the remarkable improvement in the living con-
ditions (15-18). This improvement may have contributed to a 
declining prevalence of H. Pylori infection in younger birth co-
horts (19) and the use of eradication therapy in older cohorts 
may have further contributed to the lowering of incidence 
and mortality rates (20). H. Pylori infection plays an important 
role in the sequence of events that can lead to gastric cancer 
and is classified as a type I carcinogen according to the Inter-
national Agency for Research on Cancer criteria (4).
According to the most recent data from the Croatian Nation-
al Cancer Registry, the gastric cancer crude incidence rate 
per 100 000 men in 2008 was 29.0 (617 cases), making it the 
fifth most common cancer; for women the rate was 17.0 per 
100 000 (390 cases), making it the eighth most common can-
cer (21). Among cancer-related causes of death in 2008, gas-
tric cancer ranked fourth both in men, with a crude mortality 
rate of 24.2 per 100 000 (514 deaths), and in women, with a 
crude mortality rate of 15.9 per 100 000 (364 deaths) (22).
Colorectal cancer
Colorectal cancer is a major global public health problem, 
with approximately 950 000 newly diagnosed cases each 
year (1). The risk of colorectal cancer increases steeply with 
age, and in many developed countries colorectal cancer 
burden is increasing with increasing life expectancy. The 
incidence is also increasing in many developing countries, 
as diet and lifestyle become more similar to those in devel-
oped countries. Colorectal cancer five-year relative survival 
in Europe for both sexes combined is 56.2% (23).
Family history of hereditary colorectal cancer is a recog-
nized risk factor, accounting for 15%-20% of cases at the 
population level (24). Additional 6% excess risk can be at-
tributed to genetic predisposition due to common causal 
variants in the genome (25-29). Increased colorectal can-
cer risk is also associated with dietary factors such as high 
fat and red meat consumption and low vegetable intake, 
as well as with physical inactivity, excess body weight, and 
high alcohol consumption (30). On the other hand, it has 
been inversely associated with the use of exogenous fe-
male hormones (31).
Western  European  countries  introduced  the  secondary 
cancer prevention in mid-2000s, most often based on fe-
cal occult blood test followed by colonoscopy (32). Croatia 
initiated the national colorectal cancer screening program 
in 2007. Apart from active screening, changes in colorectal 
cancer trends worldwide could be attributed to standard-
ization and availability of evidence-based surgical, chemo-, 
and radiotherapy (33,34).
The aim of this study was to analyze gastric and colorectal 
cancer incidence and mortality trends in Croatia from 1988 
to 2008 for both sexes, and to evaluate these findings in 
comparison to other European countries and in the con-
text of changing environmental and social conditions, with 
possible implications for the health policies.
MeThoDs
Data sources
Incidence data for the period 1988-2008 were obtained 
from the Croatian National Cancer Registry. The Regis-
try, founded in 1959, covers the whole Croatian popu-
lation (approximately 4.4 million persons) and relies on 
mandatory  cancer  notifications  from  primary  and  sec-
ondary health care sources and death certificates from 
the Croatian Bureau of Statistics. The Registry contrib-
uted data to the last three volumes of the Cancer In-
cidence in Five Continents series (35-37). In addition 
to incidence data, these publications report indices CANCER EPIDEMIOLOGY  126 Croat Med J. 2012;53:124-34
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of  data  quality  (proportion  of  morphologically  verified 
cases, proportion of cases registered from death certifi-
cates only, and mortality to incidence ratio). At the Reg-
istry, gastric cancer was defined as ICD-9 (38) code 151 
from 1988 to 2000 and ICD-10 (39) code C16 from 2001 
to 2008. Colorectal cancer was defined as cancer of the 
hepatic flexure (153.0), transverse colon (153.1), cecum 
(153.4), appendix (153.5), ascending colon (153.6), splenic 
flexure (153.7), descending colon (153.2), sigmoid colon 
(153.3),  recto  sigmoid  junction  (154.0),  rectum  (154.1), 
and unspecified (153.8 and 153.9) in ICD-9; and the colon 
(C18.0-C18.9), recto sigmoid junction (C19.0-C19.9), rec-
tum (C20.0-C20.9), and anus (C21) in ICD-10. The num-
ber of deaths from gastric and colorectal cancer as the 
underlying cause were obtained from the World Health 
Organization mortality database (40). For calculating age-
specific rates, we used the population estimates from the 
Population Division of the Department of Economic and 
Social Affairs of the United Nations (41).
statistical analysis
Age-standardized rates of cancer incidence in Croatia were 
calculated by the direct standardization method, using the 
world standard population as a reference (42). To describe 
incidence and mortality time trends, we carried out join-
point regression analysis using the software Joinpoint Re-
gression Program, Version 3.5.0. April 2011 (43). The anal-
ysis included the logarithmic transformation of the rates, 
standard error, maximum number of five joinpoints, and 
minimum of four years between two joinpoints. All other 
program parameters were set to default values. The aim of 
the approach is to identify possible joinpoints where a sig-
nificant change in the trend occurs. The method identifies 
joinpoints based on regression models with 0-5 joinpoints. 
The final model selected was the most parsimonious of 
these, with the estimated annual per cent change (EAPC) 
based on the trend within each segment (44). To quantify 
the trend over a fixed period, the average annual per cent 
change (AAPC) was calculated. The AAPC is computed as 
a geometric weighted average of the EAPC trend analy-
sis, with the weights equal to the lengths of each segment 
during the pre-specified fixed interval (45).
In case of non-significant trends (P > 0.05), we used the 
terms “stable” (EAPC between -0.5% to 0.5%), “non statis-
tically significant increase” (EAPC>0.5%), and “non statis-
tically  significant  decrease”  (EAPC<-0.5%).  All  statistical 
tests were two sided. Unless otherwise mentioned, the 
rates were expressed per 100 000.
ResuLTs
Gastric cancer
During the period 1988-2008, there were 25 183 cases of 
gastric cancer and 21 313 deaths. The age-standardized in-
cidence rate per 100 000 decreased from 29.5 in the first 
5-year period (1988-1992) to 16.9 in the last 5-year period 
(2004-2008) in men (43%), and from 11.7 to 7.0 in women 
(40%). The age-standardized mortality rate per 100 000 de-
creased from 25.2 to 14.8 in men (41% decrease), and from 
10.0 to 5.8 in women (42% decrease)  (Tables 1 and 2).
In both sexes, gastric cancer incidence and mortality rates 
declined steadily (Figure 1 and 2). In men, incidence rates 
decreased over the entire period (EAPC -3.2%; 95% confi-
dence interval [CI], -3.6 to -2.7), with the best fitting mod-
el having no joinpoints, while mortality rates decreased 
sharply between 1988 and 1995 (EAPC -5.0%; 95% CI, -6.5 
to  -3.4)  and  then  less  sharply  between  1995  and  2008 
(EAPC -2.5%; 95% CI, -3.1 to -1.8). In women, incidence 
rates decreased (EAPC -2.8%; 95% CI, -3.5 to -2.2), also with 
no joinpoints in the final model, and the mortality rates de-
TAbLe 1. Male gastric cancer incidence and mortality in Croatia 
in the period 1988-2008. Number of cases, crude rate and age 
standardized rate (AsR) per 100 000 (using world standard 
population)
Incidence Mortality
Year N crude rate AsR N crude AsR
1988 847 39.0 30.9 736 33.9 26.8
1989 844 38.8 29.8 752 34.5 26.9
1990 872 39.9 31.2 726 33.2 25.9
1991 821 37.3 28.6 719 32.7 24.8
1992 786 35.5 26.7 621 28.0 21.4
1993 704 31.5 23.2 678 30.4 22.3
1994 754 33.6 24.1 634 28.2 20.1
1995 756 33.6 23.0 635 28.2 19.4
1996 720 32.1 21.7 606 27.0 18.4
1997 782 35.1 23.1 627 28.1 18.6
1998 683 30.9 20.0 610 27.6 17.6
1999 831 38.0 24.3 634 29.0 18.4
2000 719 33.1 20.8 610 28.1 17.7
2001 710 32.9 20.4 573 26.5 16.2
2002 711 33.1 20.1 580 27.0 16.3
2003 718 33.5 19.9 617 28.8 16.7
2004 662 30.9 18.1 610 28.5 16.4
2005 667 31.2 17.8 556 26.0 14.9
2006 604 28.3 16.1 539 25.3 14.1
2007 628 29.5 16.4 578 27.1 15.3
2008 617 29.0 16.0 514 24.2 13.1127 Kirac et al: Gastric and colorectal cancers in Croatia
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creased over the entire period (EAPC -3.2%; 95% CI, -3.7 to 
-2.7) (Table 3).
Colorectal cancer
From 1988 to 2008, there were 25 964 cases of colorectal 
cancer in men (Table 4). The number of male colorectal 
cancer cases increased more than 2-fold, from 767 in 1988 
to 1818 in 2008, while ASR increased from 27.8 to 47.5. In 
that period, 15 983 male colorectal cancer patients died. 
The number of colorectal cancer deaths doubled, from 
509 in 1988 to 1052 in 2008, while ASR increased from 
19.0 to 26.0/100 000. Joinpoint analysis in men did not 
identify any joinpoints (Table 5 and Figure 3). The inci-
TAbLe 3. Trends in incidence and mortality of gastric cancer 
in Croatia according to joinpoint analyses, 1988-2008, by sex, 
with the estimated annual percent change (eAPC) and 95% 
confidence interval (CI)
Joinpoint analyses
trend 1 trend 2
years eAPC 95% CI years eAPC 95% CI
Men:
incidence 1988-2008 -3.2 -3.6 to -2.7
mortality 1988-1995 -5.0 -6.5 to -3.4 1995-2008 -2.5 -3.1 to -1.8
Women:
incidence 1988-2008 -2.8 -3.5 to -2.2
mortality 1988-2008 -3.2 -3.7 to -2.7
FIGuRe 1. Joinpoint analyses of incidence (rhombs) and mortality (triangles) 
for gastric cancer in Croatia in the period 1988-2008 for men. AsR  (W)– age-
standardized rate per 100 000 (using world standard population).
TAbLe 2. Female gastric cancer incidence and mortality in 
Croatia in the period 1988-2008. Number of cases, crude rate, 
and age standardized rate (AsR) per 100 000 (using world 
standard population)
Incidence Mortality
Year N crude rate AsR N crude rate AsR
1988 541 23.4 12.1 482 20.8 10.8
1989 527 22.7 12.0 458 19.7 10.5
1990 556 23.8 12.9 469 20.1 10.8
1991 503 21.4 11.2 432 18.4   9.6
1992 460 19.4 10.2 372 15.7   8.1
1993 436 18.2   9.1 398 16.6   8.3
1994 447 18.5   9.5 388 16.1   8.1
1995 504 20.8 10.1 394 16.3   8.0
1996 494 20.5   9.9 408 16.9   8.0
1997 494 20.6 10.3 393 16.4   7.9
1998 432 18.2   8.5 389 16.4   7.6
1999 466 19.8   9.2 349 14.8   6.5
2000 516 22.1 10.3 359 15.4   6.7
2001 474 20.4   9.0 374 16.1   6.9
2002 474 20.5   9.1 395 17.1   7.4
2003 435 18.8   7.7 378 16.4   6.7
2004 430 18.6   7.8 357 15.5   6.2
2005 397 17.2   7.0 350 15.2   6.1
2006 374 16.3   6.5 317 13.8   5.4
2007 397 17.3   6.8 332 14.5   5.3
2008 390 17.0   6.9 364 15.9   6.2
TAbLe 4. Male colorectal cancer incidence and mortality in 
Croatia in the period 1988-2008. Number of cases, crude rate, 
and age standardized rate (AsR) per 100 000 (using world 
standard population)
Incidence Mortality
Year N crude rate AsR  N crude rate AsR
1988 767 35.3 27.8 509 23.4 19.0
1989 729 33.5 26.2 535 24.6 19.2
1990 837 38.3 29.3 523 23.9 18.8
1991 780 35.5 27.7 522 23.7 18.0
1992 886 40.0 30.2 582 26.3 19.6
1993 876 39.2 28.5 601 26.9 19.7
1994 947 42.2 29.6 601 26.8 18.7
1995 1096 48.7 33.0 631 28.0 19.4
1996 1076 48.0 32.3 702 31.3 21.1
1997 1172 52.6 35.0 718 32.2 21.2
1998 1198 54.3 35.1 758 34.3 22.0
1999 1498 68.5 43.5 801 36.6 23.5
2000 1503 69.3 43.5 841 38.8 23.9
2001 1369 63.4 39.0 770 35.7 21.8
2002 1544 71.8 43.3 885 41.2 24.6
2003 1482 69.1 41.3 956 44.6 26.0
2004 1556 72.6 42.7 898 41.9 24.1
2005 1609 75.2 43.5 998 46.7 26.0
2006 1595 74.7 42.1 1028 48.2 27.3
2007 1626 76.3 42.9 982 46.1 25.1
2008 1818 85.5 47.5 1052 49.5 26.0CANCER EPIDEMIOLOGY  128 Croat Med J. 2012;53:124-34
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dence trend significantly increased (EAPC 2.9%; 95% CI, 
2.3 to 3.9%), as well as the mortality trend  (EAPC 2.1%; 
95% CI, 1.7 to 2.4%).
There were 20 752 cases of female colorectal cancer (Table 
6). From 1988 to 2008, the number of cases increased al-
most 2-fold, from 685 to 1254. The ASR increased from 16.4/ 
100 000 to 23.4/100 000. In the same period, 12 999 female 
colorectal cancer patients died. The number of colorectal 
cancer deaths increased from 508 in 1988 to 803 in 2008, 
while ASR increased from 11.9/100 000 to 13.1/100 000. Join-
point analysis of female colorectal cancer incidence trends 
(Table 5 and Figure 4) identified two joinpoints, in 1996 and 
1999, resulting in three separate trends: from 1988 to 1996 
FIGuRe 2. Joinpoint analyses of incidence (rhombs) and mortality (triangles) 
for gastric cancer in Croatia in the period 1988-2008 for women. AsR  (W)– 
age-standardized rate per 100 000 (using world standard population).
FIGuRe 3. Joinpoint analyses of incidence (rhombs) and mortality (triangles) 
for colorectal cancer in Croatia in the period 1988-2008 for men. AsR  (W)– 
age-standardized rate per 100 000 (using world standard population).
TAbLe 6. Female colorectal cancer incidence and mortality 
in Croatia in the period 1988-2008. Number of cases, crude 
rate, and age standardized rate (AsR) per 100 000 (using world 
standard population)
Incidence Mortality
 
Year
 
N
crude rate / 
100 000
AsR / 
100 000 N
crude rate / 
100 000
AsR / 
100 000
1988   685 29.6 16.4 508 21.9 11.91
1989   770 33.2 17.9 556 24.0 12.66
1990   811 34.8 19.4 525 22.5 11.68
1991   734 31.3 17.1 545 23.2 12.34
1992   766 32.3 17.4 518 21.8 11.27
1993   755 31.5 16.8 518 21.6 10.90
1994   827 34.3 17.9 530 22.0 10.97
1995   823 34.0 17.1 540 22.3 10.88
1996   824 34.2 17.0 553 22.9 10.79
1997   963 40.2 20.5 570 23.8 11.60
1998   986 41.5 20.2 604 25.4 11.67
1999 1186 50.4 25.1 639 27.2 12.50
2000 1197 51.3 24.0 668 28.6 12.59
2001 1072 46.2 21.7 640 27.6 11.62
2002 1116 48.2 22.6 673 29.1 12.59
2003 1213 52.5 23.5 666 28.8 11.84
2004 1143 49.5 22.0 666 28.9 11.59
2005 1237 53.7 23.7 749 32.5 12.38
2006 1175 51.1 21.9 772 33.6 12.84
2007 1215 52.9 22.9 756 32.9 12.51
2008 1254 54.7 23.4 803 35.0 13.07
TAbLe 5. Trends in incidence and mortality of colorectal cancer in Croatia according to joinpoint analyses, 1988-2008, by sex, with 
the estimated annual percent change (eAPC) and 95% confidence interval (CI)
Joinpoint analyses
Trend 1 Trend 2 Trend 3
years eAPC 95% CI years eAPC 95% CI years eAPC 95% CI
Men:
incidence 1988-2008 2.9 2.3 to 3.5
mortality 1988-2008 2.1 1.7 to 2.4
Women:
incidence 1988-1996 -0.2 -1.9 to 1.6 1996-1999 10.6 -3.7 to 27.1 1999-2008 -0.5 -1.7 to 0.7
mortality 1988-1994 -1.9 -4.1 to 0.3 1994-2008   1.1  0.5 to 1.7129 Kirac et al: Gastric and colorectal cancers in Croatia
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the trend was stable (EAPC -0.2%; 95% CI, -1.9 to 1.6%), from 
1996 to 1999 the trend showed a non-significant increase 
(EAPC 10.6%; 95% CI, -3.7 to 27.1%), and from 1999 to 2008 
the trend was again stable (EAPC -0.5; 95% CI, -1.7 to 0.7%). 
AAPC for the period from 1996 (when the first increase in 
incidence was noted) to 2008 showed a non-significant in-
crease (AAPC 2.2%; 95% CI, -1.1 to 5.6%). Joinpoint analysis of 
female colorectal cancer mortality identified one joinpoint 
in 1994, resulting in two separate trends: the trend from 
1988 to 1994 showed non-significant decrease (EAPC -1.9%; 
95% CI, -4.1 to 0.3%), while from 1994 to 2008 it showed a 
significant increase (EAPC 1.1%; 95% CI, 0.5 to 1.7%). 
DIsCussIoN
This  is  the  first  study  to  systematically  analyze  the  time 
trends of gastric and colorectal cancer incidence and mor-
tality in Croatia. We chose to use joinpoint regression mod-
eling as the optimal method to detect and depict sharp 
changes in trends, reflecting changes in cancer prevention 
and care policies.
Gastric cancer
Our analysis revealed a persistent and steady decrease in 
gastric cancer incidence and mortality rates in Croatia be-
tween 1988 and 2008, with rates at the end of the study 
period being ~ 40% lower than at the beginning. The de-
crease was observed in both men and women, and the 
trends did not level off in the recent years.
Croatia is in the upper half of the list of European countries 
according  to  age-standardized  gastric  cancer  incidence 
and mortality rates for both men and women. Accord-
ing  to  the  GLOBOCAN  database,  the  highest  incidence 
and mortality rates in Europe are observed in Belarus, Al-
bania, and Russian Federation (incidence rates between 
25-34/100 000 in men and 12-18/100 000 in women; and 
mortality  rates  between  21-30/100 000  in  men  and  10-
15/100 000 in women), with much higher rates in Central 
and Eastern European countries than in more developed 
Western or Northern European countries (1).
In the EU from 1980 to 1999, a steady and persistent de-
crease in gastric cancer mortality rates was observed (from 
18.6 to 9.8/100 000 in men and from 8.9 to 4.6/100 000 in 
women, ~ 50% for each sex) (13,46). Decreases were also 
reported between 2000 and 2005 (47). The reasons for the 
decrease are complex, and not completely understood. 
They include more varied and better nutrition, better food 
preservation (refrigeration), decreased prevalence of H. py-
lori infection due to improved living conditions and chang-
es  in  lifestyle  (48-50), and,  at  least  to  some extent,  de-
creased smoking prevalence in men (51). The lowering of 
incidence rates leads to lowering of mortality rates, with a 
possible contribution of improved medical treatment (52).
During the second half of the twentieth century, Croatian 
society experienced both industrial and nutritional chang-
es. The availability of various food products, such as fruits 
and products of animal origin, was facilitated by the intro-
duction of refrigerators (53). Progressive globalization af-
ter the war in Croatia (1991-1995) led to a smaller need for 
homemade  food  production,  which  was  heavily  salted, 
marinated, and low in antioxidants (54).
The prevalence of H. Pylori infection in Croatia in 1998 in a 
random sample of individuals aged 20-70 was 60.4%, with 
higher rates in the southern parts of the country (55). This 
is considered to be an average value, since the prevalence 
ranges from 30% in the western countries to 60%-88% in 
Asian countries (56). Unfortunately, more recent data for 
Croatia are not available.
The prevalence of smoking in 1995 was 34% among men 
and 27% among women in 18-65 age group (57), while the 
prevalence in 2003 was 34% among men and 22% among 
women in 18+ age group (58). The relatively stable pro-
portion of smokers in Croatia may indicate that the low-
ering  of  gastric  cancer  rates  was  not  influenced  by 
changes in smoking habits.
FIGuRe 4. Joinpoint analyses of incidence (rhombs) and mortality (trian-
gles) for colorectal cancer in Croatia in the period 1988-2008 for women. 
AsR  (W)– age-standardized rate per 100 000 (using world standard popu-
lation).CANCER EPIDEMIOLOGY  130 Croat Med J. 2012;53:124-34
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The use of joinpoint regression model allows a fresh ap-
proach to interpretation of trends in cancer mortality over 
a longer time period. This study, as well as other studies of 
gastric cancer trends (13,14), shows a decline in mortality, 
with no signs of leveling off in the recent years. Thus, it is 
expected that the decrease in incidence and mortality rates 
will continue (59), especially because such decreases are 
also observed in the countries that already have relatively 
low gastric cancer incidence and mortality rates, such as Ice-
land, Cyprus, and Sweden (incidence rates between 4.7-6.6 
/100 000 in men and between 2.5 and 3.1/100 000 in wom-
en; and mortality rates between 4.1-4.2/100 000 in men and 
between 1.8-2.4/100 000 in women) (1).
Colorectal cancer
The incidence trend of colorectal cancer showed a signif-
icant increase in men (EAPC 2.9%). In women, there was 
no significant change in trend, though there was a con-
stant non-significant increase. In 2008, with 1818 new cas-
es colorectal cancer was the third most common cancer in 
Croatian male population and with 1052 deaths, the sec-
ond cause of cancer mortality (21). In women, with 1254 
new cases it was the second most common cancer, and 
with 803 deaths the second cause of cancer death. Com-
pared to GLOBOCAN 2008 estimates for Europe, Croatia 
ranked ninth according to incidence of colorectal cancer 
(ASR 44.4/100 000) in men and fifteenth (ASR 24.3/100 000) 
in women, but fourth according to mortality in both men 
(ASR 25.4/100 000) and women (ASR 13.1/100 000) (1).
Incidence trends vary across Europe, with persistent in-
creases or no change in Eastern European countries and 
persistent  slight  decreases  in Western  Europe  (17). The 
increase in the incidence in Eastern Europe (eg, Slovakia 
or Czech Republic, as well as Croatia) could be attributed 
to lifestyle changes, presumably introduced by western-
ization, resulting in obesity and physical inactivity (60). In 
fact, in 2003 over 1.3 million people in Croatia were either 
obese or overweight (61). The observed variations of the 
incidence rates of colorectal cancer reflect the distribu-
tions of risk factors across European countries, as well as 
disparities in the effective cancer prevention and detec-
tion (62). However, such results should be interpreted with 
caution since all registries from which the data have been 
obtained do not comply with quality requirements, and 
a substantial number of Eastern European countries eg, 
Greece, Bosnia and Herzegovina, FYR Macedonia, and Ro-
mania, do not have established national cancer regis-
tration (63).
In  the  European  Union,  colorectal  cancer  mortality  has 
been declining since the early 1980s by around 1% per 
year in women, and since the early 1990s by 0.6% per year 
in men (64). Decreases were found in Austria, Finland, Ire-
land, Netherlands, Norway, Sweden, Switzerland, United 
Kingdom, France, and Italy, and even earlier in Belgium, 
Germany, and Denmark (65). On the other hand, increases 
were observed in Bulgaria, Poland, Romania, Greece, Portu-
gal, and Spain. In the Czech Republic, Slovakia, and Hunga-
ry, the rates were exceedingly high, but remained constant 
in the recent years (65).
Incidence and the mortality rates may also be affected 
by screening and early detection. All but three countries 
(Greece, Russia, and Turkey) (66-68) participate in some 
form  of  colorectal  cancer  screening.  However,  only  five 
European countries have an organized population-based 
screening program (Croatia, Finland, France, Italy, the UK) 
(69-72) and only five have screening guidelines – Finland, 
France, Germany (73), Italy, and the UK. There is still room 
for improvement since the participation rate in the vol-
untary screening is 15% and up to 60% in the organized 
screening programs (74). In the Croatian national screen-
ing, the participation rate was 19.9% (69).
Several randomized trials and one Cochrane review pro-
vided strong evidence that fecal occult blood test followed 
by colonoscopy, if offered every 2 years, reduced mortal-
ity rates associated with colorectal cancer by 16% (75,76). 
In the United States, where screening was introduced in 
the 1970s, long-term screening programs have played a 
relevant role in reducing colorectal cancer incidence and 
mortality over the last two decades. One of the explana-
tions for better survival rates in the United States is an in-
creased detection and removal of colorectal polyps, which 
often precede colorectal cancer development. Screening 
programs have been implemented in Europe, including 
Croatia, only recently, so their impact on the incidence and 
mortality may become more visible in the future (76). Nev-
ertheless, increased patient awareness of signs and symp-
toms, recognition in the primary care, and access to diag-
nostic modalities may have already played a role.
In the past ten years, countries across the EU have initi-
ated national policies for improvement in diagnostics, re-
ferral, and assurance of quality of care in specialized cen-
ters with attending multidisciplinary cancer teams. The 
main goals were to improve survival and quality of life 
and to reduce regional differences in treatment options. 
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has implemented specialization of cancer services, which 
proved to be closely related to a reduction in mortality. 
Another important step is the shortening of the period 
between the symptom appearance and the referral to di-
agnostics (33).
Another important factor that explains the observed pat-
terns of survival and mortality, alongside screening, is the 
progress in therapy (77). The general improvement in sur-
gical techniques for localized and metastatic tumors sub-
stantially prolonged survival (78,79). Only the adoption of 
surgical training (subspecialization) and pathological evalu-
ation of specimens (quality control) in rectal cancer man-
agement  resulted  in  an  overall  improvement  in  survival 
(34,80,81). The wider adoption of new treatment protocols 
and adjuvant therapies, including progressive increase in 
sequential adjuvant chemotherapy for advanced non-lo-
calized tumors, and preoperative chemo- and radiotherapy 
for rectal cancers (82), may have favorably influenced col-
orectal cancer mortality (47,77,83,84). Moreover, in the past 
fifteen years five new drugs have been introduced (85,86).
We believe that the discrepancy between the incidence 
(9th in male and 15th in female colorectal cancer) and 
mortality (4th for both sexes) rank of Croatia in Europe 
strongly indicates the need for improvement of preven-
tion and treatment.
There  are  still  no  standardized  protocols  for  treatment 
and referral, or requirements for the availability of multi-
disciplinary teams for colorectal cancer treatment in most 
Croatian hospitals, with the exception of university hospi-
tals. Due to the high incidence and increasing mortality, 
Croatian Society of Coloproctology and Croatian Society 
of Oncology have launched an incentive for quality control 
and referral improvements for colorectal cancer patients, 
recognizing the current lack of availability of all treatment 
modalities at different hospitals (87). Hopefully, establish-
ing  accrediting  centers  for  colorectal  cancer  treatment 
with trained staff would ensure that every patient receives 
optimal surgical, neo adjuvant or adjuvant treatment, sys-
temic and local (radiotherapy), and regular follow-up.
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